Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186514 | 1.00 | HPGD (0.57) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL4186518 | 1.00 | HPGD (0.57) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL4711418 | 0.94 | HPGD (0.55) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL803395 | 0.88 | MEN1 (0.52) | HPGDEPHX1RECQLUSP30USP2 | |
| SCHEMBL34473736 | 0.88 | MEN1 (0.52) | HPGDEPHX1RECQLUSP30USP2 | |
| SCHEMBL1189041 | 0.88 | MEN1 (0.52) | HPGDEPHX1RECQLUSP30USP2 | |
| SCHEMBL19717593 | 0.87 | HPGD (0.56) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL2953243 | 0.84 | EPHX1 (0.58) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL12071952 | 0.84 | USP30 (0.57) | HPGDEPHX1RECQLGPR119USP30 | |
| SCHEMBL2499421 | 0.84 | USP30 (0.57) | HPGDEPHX1RECQLGPR119USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | AMGEN INC. (US) | 2009-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227601-A1 | Bradykinin 1 Receptor Antagonists | BDKRB1, BDKRB2, VIPR1 | HPGD 520/4885EPHX1 511/4885RECQL 2834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.